Eribulin gemcitabine combination therapy in previously treated patients with advanced liposarcoma or leiomyosarcoma

Effective systemic treatment options are largely limited for previously treated liposarcoma and leiomyosarcoma. In this phase II study, the eribulin gemcitabine combination therapy demonstrated appreciable efficacy compared to monotherapy from the historic arm. Functional enrichment in the transforming growth factor beta pathway would hold predictive value for the survival outcomes of the combination therapy, although further confirmatory investigation may be required. Eribulin gemcitabine combination therapy could present as a future treatment option for refractory soft tissue sarcomas with liposarcoma or leiomyosarcoma histology.